Galena, ImmunoCellular Caught Up In US SEC Clampdown On Fraudulent Stock Promotions
Executive Summary
Four biopharma firms allegedly paid writers to post positive articles about their stocks that were merely "paid advertisements"; in settlement, former CEOs of Galena and ImmunoCellular barred from being officer or director for five years and ordered to pay $1.3m and $2.9m, respectively.